Stryker Corporation (NYSE:SYK) insider Graham A. Mclean sold 1,124 shares of the firm’s stock in a transaction that occurred on Tuesday, August 8th. The stock was sold at an average price of $146.26, for a total transaction of $164,396.24. Following the sale, the insider now owns 8,983 shares of the company’s stock, valued at $1,313,853.58. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Shares of Stryker Corporation (SYK) traded down 0.66% on Wednesday, reaching $145.18. 1,080,989 shares of the company were exchanged. The firm has a 50 day moving average price of $143.16 and a 200-day moving average price of $134.68. The stock has a market capitalization of $54.31 billion, a PE ratio of 32.41 and a beta of 0.80. Stryker Corporation has a 12-month low of $106.48 and a 12-month high of $148.84.
Stryker Corporation (NYSE:SYK) last posted its earnings results on Thursday, July 27th. The medical technology company reported $1.53 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.51 by $0.02. Stryker Corporation had a net margin of 14.22% and a return on equity of 24.26%. The business had revenue of $3.01 billion for the quarter, compared to analysts’ expectations of $2.98 billion. During the same period in the prior year, the company posted $1.39 EPS. The business’s revenue for the quarter was up 6.1% compared to the same quarter last year. On average, analysts predict that Stryker Corporation will post $6.50 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Tuesday, October 31st. Shareholders of record on Friday, September 29th will be paid a $0.425 dividend. This represents a $1.70 annualized dividend and a yield of 1.17%. The ex-dividend date of this dividend is Thursday, September 28th. Stryker Corporation’s dividend payout ratio is presently 37.95%.
COPYRIGHT VIOLATION NOTICE: This piece was originally published by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The correct version of this piece can be viewed at https://sportsperspectives.com/2017/08/10/insider-selling-stryker-corporation-syk-insider-sells-1124-shares-of-stock.html.
Several equities research analysts have issued reports on SYK shares. BMO Capital Markets restated a “hold” rating and set a $125.00 price objective on shares of Stryker Corporation in a research report on Tuesday, April 11th. Jefferies Group LLC restated a “hold” rating and set a $132.00 price objective on shares of Stryker Corporation in a research report on Thursday, April 13th. Piper Jaffray Companies restated an “overweight” rating and set a $148.00 price objective on shares of Stryker Corporation in a research report on Monday, April 17th. Needham & Company LLC restated a “sell” rating on shares of Stryker Corporation in a research report on Wednesday, April 26th. Finally, Royal Bank Of Canada restated an “outperform” rating and set a $140.00 price objective (up from $135.00) on shares of Stryker Corporation in a research report on Wednesday, April 26th. Three investment analysts have rated the stock with a sell rating, seven have given a hold rating and twelve have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $144.03.
Several institutional investors have recently modified their holdings of SYK. Personal Capital Advisors Corp bought a new position in shares of Stryker Corporation during the first quarter worth approximately $267,000. JPMorgan Chase & Co. raised its position in shares of Stryker Corporation by 276.9% in the first quarter. JPMorgan Chase & Co. now owns 269,555 shares of the medical technology company’s stock worth $35,487,000 after buying an additional 198,035 shares during the last quarter. British Columbia Investment Management Corp raised its position in shares of Stryker Corporation by 10.7% in the first quarter. British Columbia Investment Management Corp now owns 133,596 shares of the medical technology company’s stock worth $17,588,000 after buying an additional 12,871 shares during the last quarter. BNP Paribas Arbitrage SA raised its position in shares of Stryker Corporation by 462.7% in the first quarter. BNP Paribas Arbitrage SA now owns 252,230 shares of the medical technology company’s stock worth $33,206,000 after buying an additional 207,409 shares during the last quarter. Finally, Hartland & Co. LLC raised its position in shares of Stryker Corporation by 1.4% in the first quarter. Hartland & Co. LLC now owns 1,860 shares of the medical technology company’s stock worth $245,000 after buying an additional 25 shares during the last quarter. 73.99% of the stock is currently owned by hedge funds and other institutional investors.
About Stryker Corporation
Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.
Receive News & Ratings for Stryker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Corporation and related companies with MarketBeat.com's FREE daily email newsletter.